Skip to main content
Clinical Trials/NCT00939588
NCT00939588
Completed
Phase 2

An 8 Week, Double-blind, Randomized, Parallel-group Study to Compare the Effect of Aliskiren 300mg + Valsartan 320mg vs. Telmisartan 80mg + Ramipril 10mg on Biomarkers of the Renin-angiotensin-aldosterone System in Moderate Hypertension

Novartis Pharmaceuticals1 site in 1 country88 target enrollmentJuly 2009

Overview

Phase
Phase 2
Intervention
Aliskiren/ Valsartan
Conditions
Hypertension
Sponsor
Novartis Pharmaceuticals
Enrollment
88
Locations
1
Primary Endpoint
Compare the effects of aliskiren + valsartan vs ramipril + telmisartan on 24-hour urinary aldosterone
Status
Completed
Last Updated
9 years ago

Overview

Brief Summary

This study is designed as a mechanistic study to compare the effect of two different combinations of anti-hypertensive treatments (aliskiren and valsartan vs. telmisartan and ramipril) on the renin-angiotensin-aldosterone system (RAAS) in patients with moderate hypertension.

Registry
clinicaltrials.gov
Start Date
July 2009
End Date
December 2009
Last Updated
9 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Males or females of non-childbearing potential, 18 to 65 years of age with moderate hypertension
  • Patients who are eligible and able to participate in the study
  • Exclusion criteria:
  • Severe hypertension or secondary form of hypertension.
  • Serum potassium \> 5.1 mEq/L (mmol/L)
  • Heart failure
  • Any history of hypertensive encephalopathy or cerebrovascular accident; any history of TIA, myocardial infarction, coronary bypass surgery or percutaneous coronary intervention
  • Uncontrolled or life-threatening arrythmia
  • Other protocol-defined inclusion/exclusion criteria may apply

Exclusion Criteria

  • Not provided

Arms & Interventions

Aliskiren and Valsartan

Intervention: Aliskiren/ Valsartan

Telmisartan and Ramipril

Intervention: Telmisartan/ Ramipril

Outcomes

Primary Outcomes

Compare the effects of aliskiren + valsartan vs ramipril + telmisartan on 24-hour urinary aldosterone

Time Frame: 56 days

Secondary Outcomes

  • Compare the effects of aliskiren + valsartan vs ramipril + telmisartan on Plasma Renin Activity (PRA)and angiotensin II(56 days)
  • Compare the effects of aliskiren + valsartan vs ramipril + telmisartan on mean sitting systolic and diastolic blood pressure(56 days)
  • Assess safety and tolerability of aliskiren + valsartan and ramipril + telmisartan(56 days)

Study Sites (1)

Loading locations...

Similar Trials